Tolerogenic dendritic cells: Applications for solid organ transplantation

Current Opinion in Organ Transplantation

Volumn 17, Issue 1, 2012, Pages 42-47

  Beriou, Gaelle ^a   Moreau, Aurelie ^a   Cuturi, Maria C ^a  

^a HÔTEL DIEU   (France)

Author keywords

cell therapy; tolerance; tolerogenic dendritic cells; transplantation

Indexed keywords

ALLOANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RAPAMYCIN; TACROLIMUS;

ALLOIMMUNITY; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; AUTOTRANSPLANTATION; BONE MARROW CELL; CELL THERAPY; DENDRITIC CELL; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; MESENCHYMAL STEM CELL; MONOCYTE; NONHUMAN; ORGAN TRANSPLANTATION; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; TOLEROGENIC DENDRITIC CELL; TOLEROGENIC DENDRITIC CELL THERAPY; TRANSPLANTATION TOLERANCE;

ANIMALS; ANTIGENS, CD; DENDRITIC CELLS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY, ADOPTIVE; MACROPHAGES; ORGAN TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84856087908     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32834ee662     Document Type: Review

References (39)

1. Lombardi G, Sagoo P, Scotta C, et al. Cell therapy to promote transplantation tolerance: A winning strategy? Immunotherapy 2011; 3:28-31.
2. Ezzelarab M, Thomson AW. Tolerogenic dendritic cells and their role in transplantation. Semin Immunol 2011; 23:52-63.
3. van Kooten C, Lombardi G, Gelderman KA, et al. Dendritic cells as a tool to induce transplantation tolerance: obstacles and opportunities. Transplantation2011; 91:2-7.
4. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7:610-621. (Pubitemid 47123548)
5. Fu F, Li Y, Qian S, et al. Costimulatory molecule-deficient dendritic cell progenitors (MHC class II, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation 1996; 62: 659-665. (Pubitemid 26313912)
6. Lu L, Li W, Fu F, et al. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation 1997; 64:1808-1815.
7. Lutz MB, Suri RM, Niimi M, et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000; 30:1813-1822. (Pubitemid 30456177)
8. Divito SJ, Wang Z, Shufesky WJ, et al. Endogenous dendritic cells mediate the effects of intravenously injected therapeutic immunosuppressive dendritic cells in transplantation. Blood 2010; 116:2694-2705.
9. Taner T, Hackstein H, Wang Z, et al. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005; 5:228-236. (Pubitemid 40179509)
10. 3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178:7018-7031. (Pubitemid 46847428)
11. Dudziak D, Kamphorst AO, Heidkamp GF, et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007; 315:107-111. (Pubitemid 46196991)
12. Tanriver Y, Ratnasothy K, Bucy RP, et al. Targeting MHC class I monomers to dendritic cells inhibits the indirect pathway of allorecognition and the production of IgG alloantibodies leading to long-term allograft survival. J Immunol 2010; 184:1757-1764.
13. Hill M, Cuturi MC. Negative vaccination by tolerogenic dendritic cells in organ transplantation. Curr Opin Organ Transplant 2010; 15:738-743.
14. Hill M, Segovia M, Cuturi MC. What is the role of antigen-processing mechanisms in autologous tolerogenic dendritic cell therapy in organ transplantation? Immunotherapy 2011; 3:12-14.
15. Peche H, Trinite B, Martinet B, Cuturi MC. Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors. Am J Transplant 2005; 5:255-267. (Pubitemid 40179512)
16. Beriou G, Peche H, Guillonneau C, et al. Donor-specific allograft tolerance by administration of recipient-derived immature dendritic cells and suboptimal immunosuppression. Transplantation 2005; 79:969-972. (Pubitemid 40586872)
17. Hill M, Thebault P, Segovia M, et al. Cell therapy with autologous tolerogenic dendritic cells induces allograft tolerance through IFN-gamma and EBI3. Am J Transplant 2011; 11:2036-2045.
18. Segovia M, Cuturi MC, Hill M. Preparation of mouse bone marrow-derived dendritic cells with immunoregulatory properties. Methods Mol Biol 2011; 677:161-168.
19. Moreau A, Hill M, Thebault P, et al. Tolerogenic dendritic cells actively inhibit T cells through heme oxygenase-1 in rodents and in nonhuman primates. FASEB J 2009; 23:3070-3077.
20. Yu G, Xu X, Vu MD, et al. NK cells promote transplant tolerance by killing donor antigen-presenting cells. J Exp Med 2006; 203:1851-1858. (Pubitemid 44188459)
21. Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004; 4:24-34. (Pubitemid 38084129)
22. Naranjo-Gomez M, Raich-Regue D, Onate C, et al. Comparative study of clinical grade human tolerogenic dendritic cells. J Transl Med 2011; 9:89.
23. Chitta S, Santambrogio L, Stern LJ.GMCSF in the absence of other cytokines sustains human dendritic cell precursors with T cell regulatory activity and capacity to differentiate into functional dendritic cells. Immunol Lett 2008; 116:41-54.
24. Gregori S, Tomasoni D, Pacciani V, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 2010; 116:935-944.
25. 4+ T cells by alternatively activated dendritic cells. J Leukoc Biol 2008; 84:124-133. (Pubitemid 351960287)
26. Anderson AE, Swan DJ, Sayers BL, et al. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol 2009; 85:243-250.
27. Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterization of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis 2010; 69:2042-2050.
28. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193:233-238. (Pubitemid 32524454)
29. 8+ regulatory T cells in vivo in humans. Blood 2002; 100:174-177. (Pubitemid 35177444)
30. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: Mapping the way. Nat Med 2004; 10:475-480. (Pubitemid 38667904)
31. Giannoukakis N, Phillips B, Finegold D, et al. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011; 34:2026-2032.
32. Machen J, Harnaha J, Lakomy R, et al. Antisense oligonucleotides downregulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol 2004; 173:4331-4341. (Pubitemid 39280661)
33. Liang X, Lu L, Chen Z, et al. Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival. Transplantation 2003; 76:721-729. (Pubitemid 37072011)
34. Thomson AW, Robbins PD. Tolerogenic dendritic cells for autoimmune disease and transplantation. Ann Rheum Dis 2008; 67 (Suppl 3):iii90-iii96.
35. Hilkens CM, Isaacs JD, Thomson AW. Development of dendritic cellbased immunotherapy for autoimmunity. Int Rev Immunol 2010; 29:156-183.
36. Zahorchak AF, Kean LS, Tokita D, et al. Infusion of stably immature monocytederived dendritic cells plus CTLA4Ig modulates alloimmune reactivity in rhesus macaques. Transplantation 2007; 84:196-206. (Pubitemid 47205753)
37. Sordi V, Bianchi G, Buracchi C, et al. Differential effects of immunosuppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: selective upregulation by rapamycin. Transplantation 2006; 82: 826-834. (Pubitemid 44470386)
38. Lee YR, Yang IH, Lee YH, et al. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 2005; 105:3951-3955.
39. Kirsch BM, Haidinger M, Zeyda M, et al. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients. Transpl Immunol 2006; 16:254-257. (Pubitemid 44809916)